431 related articles for article (PubMed ID: 19078993)
21. Evaluation of E1A double mutant oncolytic adenovectors in anti-glioma gene therapy.
Ulasov IV; Tyler MA; Rivera AA; Nettlebeck DM; Douglas JT; Lesniak MS
J Med Virol; 2008 Sep; 80(9):1595-603. PubMed ID: 18649343
[TBL] [Abstract][Full Text] [Related]
22. Combination of adenoviral virotherapy and temozolomide chemotherapy eradicates malignant glioma through autophagic and apoptotic cell death in vivo.
Ulasov IV; Sonabend AM; Nandi S; Khramtsov A; Han Y; Lesniak MS
Br J Cancer; 2009 Apr; 100(7):1154-64. PubMed ID: 19277041
[TBL] [Abstract][Full Text] [Related]
23. Single dose GLP toxicity and biodistribution study of a conditionally replicative adenovirus vector, CRAd-S-pk7, administered by intracerebral injection to Syrian hamsters.
Kim JW; Auffinger B; Spencer DA; Miska J; Chang AL; Kane JR; Young JS; Kanojia D; Qiao J; Mann JF; Zhang L; Wu M; Ahmed AU; Aboody KS; Strong TV; Hébert CD; Lesniak MS
J Transl Med; 2016 May; 14(1):134. PubMed ID: 27184224
[TBL] [Abstract][Full Text] [Related]
24. Treatment of malignant gliomas with a replicating adenoviral vector expressing herpes simplex virus-thymidine kinase.
Nanda D; Vogels R; Havenga M; Avezaat CJ; Bout A; Smitt PS
Cancer Res; 2001 Dec; 61(24):8743-50. PubMed ID: 11751394
[TBL] [Abstract][Full Text] [Related]
25. Targeting mesothelioma using an infectivity enhanced survivin-conditionally replicative adenoviruses.
Zhu ZB; Makhija SK; Lu B; Wang M; Wang S; Takayama K; Siegal GP; Reynolds PN; Curiel DT
J Thorac Oncol; 2006 Sep; 1(7):701-11. PubMed ID: 17409940
[TBL] [Abstract][Full Text] [Related]
26. Viruses, gene therapy and stem cells for the treatment of human glioma.
Kyritsis AP; Sioka C; Rao JS
Cancer Gene Ther; 2009 Oct; 16(10):741-52. PubMed ID: 19644531
[TBL] [Abstract][Full Text] [Related]
27. Tamoxifen improves cytopathic effect of oncolytic adenovirus in primary glioblastoma cells mediated through autophagy.
Ulasov IV; Shah N; Kaverina NV; Lee H; Lin B; Lieber A; Kadagidze ZG; Yoon JG; Schroeder B; Hothi P; Ghosh D; Baryshnikov AY; Cobbs CS
Oncotarget; 2015 Feb; 6(6):3977-87. PubMed ID: 25738357
[TBL] [Abstract][Full Text] [Related]
28. Mesenchymal Stem Cells Successfully Deliver Oncolytic Virotherapy to Diffuse Intrinsic Pontine Glioma.
Chastkofsky MI; Pituch KC; Katagi H; Zannikou M; Ilut L; Xiao T; Han Y; Sonabend AM; Curiel DT; Bonner ER; Nazarian J; Horbinski CM; James CD; Saratsis AM; Hashizume R; Lesniak MS; Balyasnikova IV
Clin Cancer Res; 2021 Mar; 27(6):1766-1777. PubMed ID: 33272983
[TBL] [Abstract][Full Text] [Related]
29. The human survivin promoter: a novel transcriptional targeting strategy for treatment of glioma.
Van Houdt WJ; Haviv YS; Lu B; Wang M; Rivera AA; Ulasov IV; Lamfers ML; Rein D; Lesniak MS; Siegal GP; Dirven CM; Curiel DT; Zhu ZB
J Neurosurg; 2006 Apr; 104(4):583-92. PubMed ID: 16619663
[TBL] [Abstract][Full Text] [Related]
30. Defining a murine ovarian cancer model for the evaluation of conditionally-replicative adenovirus (CRAd) virotherapy agents.
González-Pastor R; Ashshi AM; El-Shemi AG; Dmitriev IP; Kashentseva EA; Lu ZH; Goedegebuure SP; Podhajcer OL; Curiel DT
J Ovarian Res; 2019 Feb; 12(1):18. PubMed ID: 30767772
[TBL] [Abstract][Full Text] [Related]
31. Incorporating the survivin promoter in an infectivity enhanced CRAd-analysis of oncolysis and anti-tumor effects in vitro and in vivo.
Zhu ZB; Makhija SK; Lu B; Wang M; Rivera AA; Kim-Park S; Ulasov IV; Zhou F; Alvarez RD; Siegal GP; Curiel DT
Int J Oncol; 2005 Jul; 27(1):237-46. PubMed ID: 15942665
[TBL] [Abstract][Full Text] [Related]
32. Oncolytic Virotherapy for the Treatment of Malignant Glioma.
Foreman PM; Friedman GK; Cassady KA; Markert JM
Neurotherapeutics; 2017 Apr; 14(2):333-344. PubMed ID: 28265902
[TBL] [Abstract][Full Text] [Related]
33. Cancer-specific targeting of a conditionally replicative adenovirus using mRNA translational control.
Stoff-Khalili MA; Rivera AA; Nedeljkovic-Kurepa A; DeBenedetti A; Li XL; Odaka Y; Podduturi J; Sibley DA; Siegal GP; Stoff A; Young S; Zhu ZB; Curiel DT; Mathis JM
Breast Cancer Res Treat; 2008 Mar; 108(1):43-55. PubMed ID: 17508279
[TBL] [Abstract][Full Text] [Related]
34. Development of an optimized conditionally replicative adenoviral agent for ovarian cancer.
Zhu ZB; Lu B; Park M; Makhija SK; Numnum TM; Kendrick JE; Wang M; Tsuruta Y; Fisher P; Alvarez RD; Zhou F; Siegal GP; Wu H; Curiel DT
Int J Oncol; 2008 Jun; 32(6):1179-88. PubMed ID: 18497979
[TBL] [Abstract][Full Text] [Related]
35. Survivin promoter-based conditionally replicative adenoviruses target cholangiocarcinoma.
Zhu ZB; Chen Y; Makhija SK; Lu B; Wang M; Rivera AA; Yamamoto M; Wang S; Siegal GP; Curiel DT; McDonald JM
Int J Oncol; 2006 Nov; 29(5):1319-29. PubMed ID: 17016667
[TBL] [Abstract][Full Text] [Related]
36. A targeting ligand enhances infectivity and cytotoxicity of an oncolytic adenovirus in human pancreatic cancer tissues.
Yamamoto Y; Hiraoka N; Goto N; Rin Y; Miura K; Narumi K; Uchida H; Tagawa M; Aoki K
J Control Release; 2014 Oct; 192():284-93. PubMed ID: 25108153
[TBL] [Abstract][Full Text] [Related]
37. Conditionally replicative adenoviral vectors for malignant glioma.
Sonabend AM; Ulasov IV; Lesniak MS
Rev Med Virol; 2006; 16(2):99-115. PubMed ID: 16416455
[TBL] [Abstract][Full Text] [Related]
38. A Genetically Modified Adenoviral Vector with a Phage Display-Derived Peptide Incorporated into Fiber Fibritin Chimera Prolongs Survival in Experimental Glioma.
Kim JW; Kane JR; Young JS; Chang AL; Kanojia D; Morshed RA; Miska J; Ahmed AU; Balyasnikova IV; Han Y; Zhang L; Curiel DT; Lesniak MS
Hum Gene Ther; 2015 Sep; 26(9):635-46. PubMed ID: 26058317
[TBL] [Abstract][Full Text] [Related]
39. A survivin-mediated oncolytic adenovirus induces non-apoptotic cell death in lung cancer cells and shows antitumoral potential in vivo.
Li B; Liu X; Fan J; Qi R; Bo L; Gu J; Qian Q; Qian C; Liu X
J Gene Med; 2006 Oct; 8(10):1232-42. PubMed ID: 16900558
[TBL] [Abstract][Full Text] [Related]
40. Concepts in Oncolytic Adenovirus Therapy.
Mantwill K; Klein FG; Wang D; Hindupur SV; Ehrenfeld M; Holm PS; Nawroth R
Int J Mol Sci; 2021 Sep; 22(19):. PubMed ID: 34638863
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
